Compare Expedia Group Inc (EXPE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs GeneDx Holdings Corp — how do they compare? Expedia Group Inc trades at $271.53 (market cap $32.42B), while GeneDx Holdings Corp trades at $67.75 (market cap $2.02B). The key difference: Expedia Group Inc is far larger — about 16× GeneDx Holdings Corp's market cap, and Expedia Group Inc pays a 0.71% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and GeneDx Holdings Corp for 19 Days on average.
| EXPE | WGS | |
|---|---|---|
Market Cap | $32.42B | $2.02B |
Volume | 1,940,671 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $167.51 |
52-Week Low | $188.51 | $34.51 |
Typical Hold Time | 48 Days | 19 Days |
Enterprise Value | $30.98B | $2.05B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, amid a bearish technical signal and recent news-driven volatility. The stock shows strong fundamentals with consistent earnings beats, revenue growth to $14.73B in 2025, and robust profitability margins. Recent layoffs and competitive threats from AI travel agents have pressured sentiment, but analyst consensus remains largely positive with a $335.06 price target.
The outlook balances solid financial health and attractive valuation against near-term competitive and execution risks. Upside potential exists if Expedia navigates AI disruption and sustains booking growth, but investor caution is warranted given technical weakness and industry headwinds.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
